What is Oncogen XP-180?

INTRODUCTION - oncogen XP-180 or XP-180

Cancer is still one of the fatal diseases. In Hong Kong, lung carcinoma is the first killer among carcinomas. It is believed that both active smokers and passive smokers are having a higher incidence of getting lung carcinoma than non-smoker. Although breast cancer is more common in Western part of the world, its increasing rate in East Asia also makes warning to people. The rate of occurrence of hepatocellular carcinoma (HCC) is relatively high in East Asia (1). Many factors, including hepatitis B infection and liver cirrhosis, increase the rate of HCC formation (2,3). HCC pathogenesis is enhanced by the intake of alfatoxin (4). Many fermented crops are believed to be rich in aflatoxin (5). Environmental pollution has been shown to play an important role in leukaemogenesis.


Nowadays, the use of microbial fermentation products as anti-cancer regimens is sought in additional to natural herbal medicine as their qualities are under control in both laboratory and industrial standards (6). Of these, we have demonstrated that the effective microogranism extract (EM-X) and Phaffia rhodozyma (Xanthophyllomyces denrorhous) extract fermented by brewer malt waste are active in growth inhibition and induction of cell death on different types of cancer cells in vitro (7-9). Both of them could posses strong anti-oxidation activity. Here we have screened the possible anti-cancer potential of a microbial fermentation extract called Oncogen XP-180 (or simply as XP-180) on various solid tumour including non-small cell lung cancer, breast cancer and hepatoma as well as acute myelogenous leukaemia (AML) cell lines. Our results suggested that XP-180 is effective in anti-proliferative and apoptotic induction in cancer cell lines. Furthermore, XP-180 could significantly reduce the regeneration potential of cancer cells while both caspase dependent and independent pathways are active in XP-180 induced apoptosis.


For more info please contact me or post a comment here.

Thank You

In vitro anti-cancer activity of a novel microbial fermentation product on human carcinomas.

Anti-Cancer Research Center, State Key Laboratory of Chinese Medicine and Molecular Pharmacology, Department of Applied Biology, and Chemical Technology, The Hong Kong Polytechnic University, PR China.

The possible anti-proliferation and cell death induction potential of a novel microbial fermentation extract named as oncogen XP-180 (or simply as XP-180) was tested on three human solid tumour carcinoma cell lines (non-small cell lung cancer A549, breast cancer MDA-MB231, liver adenocarcinoma SK-Hep1) and on the acute myelogenous leukaemia KG1a cell line. Anti-proliferative activity of XP-180 was observed on all of these cancer cell lines with comparable efficiency and in a dose-dependent manner. Morphological investigation further suggested that common features of apoptosis, including cell shrinkage and rounding, are present in XP-180 treated cells. Loss of adhesion properties of these solid tumour cell lines was observed upon XP-180 incubation. Anchorage-dependent clonogenicity assay on solid tumour cell lines and semi-solid methylcellulose colony formation assay on leukaemia cell line further revealed that XP-180 strongly inhibited the regeneration potential of these cancer cells. Using KG1a as an experimental model system, XP-180 was shown to stimulate the activity of caspase 3, 8 and 9 without significant change in caspase 6 activity. Furthermore, XP-180 readily induced collapse of mitochondrial membrane potential after 2 h of incubation. However, the use of the generic caspase specific inhibitor Z-VAD-FMK does not significantly reverse XP-180 mediated cell death. The results obtained suggest that XP-180-mediated cancer cell death could involve mitochondria and both caspase-dependent and -independent pathways.
Therefore, XP-180 is an efficient anti-cancer regimen in vitro.

PMID: 16525727 [PubMed - indexed for MEDLINE]
Int J Mol Med. 2006 Apr ;17:675-679

Cancer apoptosis induced by novel microbial fermentation product

Vaccine Weekly via NewsEdge Corporation :

2006 MAY 17 - NewsRx.com -- Cancer apoptosis was induced by the anti-cancer activity of a novel microbial fermentation product.

According to recent research from the People's Republic of China, "The possible anti-proliferation and cell death induction potential of a novel microbial fermentation extract named as oncogen XP-180 (or simply as XP-180) was tested on three human solid tumor carcinoma cell lines (non-small cell lung cancer A549, breast cancer MDA-MB231, liver adenocarcinoma SK-Hep1) and on the acute myelogenous leukaemia KG1a cell line. Anti-proliferative activity of XP-180 was observed on all of these cancer cell lines with comparable efficiency and in a dose-dependent manner."

"Morphological investigation further suggested that common features of apoptosis, including cell shrinkage and rounding, are present in XP-180 treated cells," explained C.H. Chui and colleagues, Chinese University of Hong Kong. "Loss of adhesion properties of these solid tumor cell lines was observed upon XP-180 incubation. Anchorage-dependent clonogenicity assay on solid tumor cell lines and semi-solid methylcellulose colony formation assay on leukaemia cell line further revealed that XP-180 strongly inhibited the regeneration potential of these cancer cells.

"Using KG1a as an experimental model system, XP-180 was shown to stimulate the activity of caspase 3, 8 and 9 without significant change in caspase 6 activity. Furthermore, XP-180 readily induced collapse of mitochondrial membrane potential after 2 h of incubation. However, the use of the generic caspase specific inhibitor Z-VAD-FMK does not significantly reverse XP-180 mediated cell death."

The researchers concluded, "The results obtained suggest that XP-180-mediated cancer cell death could involve mitochondria and both caspase-dependent and-independent pathways. Therefore, XP-180 is an efficient anti-cancer regimen in vitro."

Chui and colleagues published their study in International Journal of Molecular Medicine (In vitro anti-cancer activity of a novel microbial fermentation product on human carcinomas. Int J Mol Med, 2006;17(4):675-679).

For additional information, contact G.Y.M. Cheng, Chinese University of Hong Kong, Prince Wales Hospital, Dept. Med & Therapeutic, Ngan Shing St., Shatin, Hong Kong, People's Republic of China.

Publisher contact information for the International Journal of Molecular Medicine is: Professor D.A. Spandidos, 1, S Merkouri St., Editorial Office, Athens 116 35, Greece.

Keywords: Hong Kong, People's Republic of China, Apoptosis, Breast Cancer, Anti-Cancer Activity, Breast Carcinoma, Lung Cancer, Lung Carcinoma, Neoplasms, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Oncology, Tumors, Women's Health, Oncogen XP-180, Mitochondria.

This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2006, Vaccine Weekly via NewsRx.com.Vaccine Weekly -- 05/18/06